{{Rsnum
|rsid=6948
|Gene=CASP3
|Chromosome=4
|position=184627976
|Orientation=minus
|GMAF=0.4412
|Gene_s=CASP3
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 23.8 | 42.9 | 33.3
| HCB | 0.0 | 0.0 | 0.0
| JPT | 63.3 | 30.3 | 6.4
| YRI | 0.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 35.1 | 56.7 | 8.2
| LWK | 0.0 | 0.0 | 0.0
| MEX | 38.6 | 50.9 | 10.5
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=22568453
|Title=Association of CASP3 polymorphism with hematologic toxicity in advanced NSCLC patients treated with platinum-based chemotherapy
}}

{{PMID|17071630}} Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma.

{{PMID|18381704|OA=1
}} Caspase polymorphisms and genetic susceptibility to multiple myeloma.

{{PMID|18829519|OA=1
}} CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck.

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}